Skip to content

Long-term Effects of High-dose Intravenous Methylprednisolone Pulse Therapy on Thyroid-associated Ophthalmopathy

Long-term Effects of High-dose Intravenous Methylprednisolone Pulse Therapy on Thyroid-associated Ophthalmopathy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-13003666
Enrollment
Unknown
Registered
2013-05-29
Start date
2013-10-08
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid-associated ophthalmopathy

Interventions

Sponsors

First Affiliated Hospital of Xi’an Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
11 Years to 74 Years

Inclusion criteria

Inclusion criteria: 1. Moderately to severely active TAO; 2. CAS score is equal or more than 4; 3. The grade of NOSPECS is equal or more than 40; 4. The disease becomes serious in the nearly three months, including the aggravation of some already existing symptoms or signs and/or the emergence of new-onset symptoms or signs; 5. There is no need to do the operation of orbital decompression, after the ophthalmologist' assessment; 6. All of the patients were informed of the possible short- and long-term sideeffects of high-dose IVMP therapy, and they all voluntarily joined this study with informed consents.

Exclusion criteria

Exclusion criteria: 1. Patients who were infected by fungus,mycobacterium tuberculosis,hepatitis virus and/or any other uncontrolled bacterium,virus and fungus; 2. Patients who are allergic to methylprednisolone; 3. Patients who have a history of serious mental disease and/or epilepsy; 4. Patients who is suffering from one or two complications, including an active peptic ulcer, a recent gastrointestinal surgery, serious diabetes, hypertension, hyperlipidemia, glaucoma, osteoporosis, heart disease, cardiac failure, hepatic impairment, impaired renal function and urolithiasis; 5. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
diplopia;visual acuity;eyeball activity;proptosis;CAS;TRAb;sICAM-1;

Secondary

MeasureTime frame
eyelid swelling;ophthalmodynia;photophobia;lacrimation;

Countries

China

Contacts

Public ContactBingyin Shi
shibingy@126.com+86 029-85323974

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026